Stocky turns companies like IMMUNO-BIOLOGICAL LABORATORIES into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Hold. 4570.T scores evenly across growth (60.5) and value (60) metrics, suggesting balanced but unremarkable fundamentals. Leadership alignment at 59/100 raises questions about founder-CEO incentive lockup and dilution trends, while a Vulnerability Index of 100—unassessed—leaves material business risks opaque. Without clear competitive moat or earnings acceleration, this is a patience-required holding rather than a conviction buy.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for IMMUNO-BIOLOGICAL LABORATORIES :
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 62/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates IMMUNO-BIOLOGICAL LABORATORIES (4570.T) at 62/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. 4570.T scores evenly across growth (60.5) and value (60) metrics, suggesting balanced but unremarkable fundamentals. Leadership alignment at 59/100 raises questions about founder-CEO incentive lockup and dilution trends, while a Vulne
4570.T's current Stocky Verdict is 62/100, placing it in the "Hold" band. This composite combines a 61/100 Compounder score, 59/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for IMMUNO-BIOLOGICAL LABORATORIES yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
IMMUNO-BIOLOGICAL LABORATORIES scores 59/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
IMMUNO-BIOLOGICAL LABORATORIES 's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to IMMUNO-BIOLOGICAL LABORATORIES .
Sign up free and unlock the full analysis on 4570.T — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 4570.T in the app.
